Current research hypothesizes PD as a compilation of complex interactions between genetic and environmental factors. PD was historically considered sporadic in nature, without genetic origin. In the past decade, however, genetic studies performed in various geographical regions worldwide have strengthened the hypothesis that PD has a substantial genetic component. Numerous genes have unequivocally been tied to familial PD, including SNCA, PRKN, PINK1, DJ1, LRRK2, ATP13A2, and PLA2G6. 4, 5 This "familial form" of PD, however, accounts for only a small percentage of overall PD diagnoses.
The majority of PD cases are considered a "sporadic form" of disease,
indicating that additional factors may also contribute to the risk of PD.
Current evidence suggests an association between glutamate-mediated excitatory neurotoxicity and neurodegenerative diseases. [6] [7] [8] The excitatory effects of glutamate are exerted via activation of ionotropic receptors, mainly at NMDA receptors (NMDARs). NMDAR channels are heteromers composed of the key receptor subunit, NMDAR1, with one or more of the four NMDAR2 subunits: NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D. 9 Continuous activation of large numbers of NMDARs can lead to elevated intracellular calcium and catabolic enzyme activity, which triggers a cascade of events leading to cell death. These event cascades include mitochondrial membrane depolarization, caspases activation, cellular toxicity, and production of reactive oxygen species and nitrogen free radicals. 8 A growing body of evidence supports an essential role for oxidative stress in the initiation and progression of neurodegeneration in PD. [10] [11] [12] The substantia nigra pars compacta (SNPC), the location of the primary pathological lesion, is predisposed to oxidative stress as well as toxic and metabolic insults. 8 One hypothesis suggests that mitochondria genetic alterations lead to impaired mitochondrial function and, therefore, degeneration of SNPC. 11, 12 Oxidative stress may also be mediated by NMDAR-induced production of reactive oxygen species, such as peroxide, hydroxyl radical, and superoxide. Animal studies have shown that both competitive and non-competitive antagonism at the NMDAR lead to an anti-parkinsonism effect. 13 Currently, only one anti-glutamatergic pharmacotherapy, amantadine, is used clinically to treat PD. Amantadine has been shown to noncompetitively block NMDARs at therapeutic concentrations in the central nervous system, supporting the association between NMDA and PD. 13 Unfortunately, the precise role of NMDAR-mediated excitotoxicity in PD progression has not been established and thus remains unclear.
With this supporting data, we hypothesized that dopaminergic neuronal degeneration seen in PD could result from a single nucleotide polymorphism (SNP) in the NMDAR. The glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) gene encodes for an epsilon subunit of NMDAR (ie, NMDAR2A). No studies have focused on an association between the SNP of the GRIN2A gene and PD susceptibility. However, four studies to date have established an interaction between rs4998386 polymorphisms of the GRIN2A gene and caffeine on PD risk. Though these studies were not performed to establish association between GRIN2A rs4998386 SNP and PD, we extracted relevant data from these studies to perform a meta-analysis exploring the relationship between the rs4998386 SNP of the GRIN2A gene and PD susceptibility.
| MATERIAL S AND ME THODS
This meta-analysis was conducted in accordance with the guidance of the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement. 14 All collected data were extracted from published studies, without ethical issues.
| Literature search
We searched PubMed, EMBASE, Web of Science, Google Scholar, 
| Eligibility criteria
Studies conducted on human subjects were included, without limitation of study language. In this meta-analysis, all included studies met the following criteria: (a) studies focused on the association between rs4998386 polymorphism and PD susceptibility, (b) patients with PD were diagnosed using standard diagnostic criteria by a neurologist, and (c) there were sufficient data of the genotypes in the case-control groups to evaluate the odds ratios (ORs) and 95% confidence intervals (CIs). The exclusion criteria were: (a) publications with overlapping cases and controls from a similar study, (b) no genotypic data available, and (c) publications with patients with other forms of parkinsonism.
| Data abstraction and assessment of methodological quality
Relevant data from each study, along with their supplementary files, were independently extracted by two reviewers (G. N. and R. O.) using a standardized, structured methodology that included the following: first author, type of design, site of study, patient ethnicity, year of publication, sample size of cases and controls, control design, Hardy-Weinberg equilibrium, source of DNA, genotyping method, and data of the genotypes in the case-control groups. The methodological quality of each study was assessed independently by two reviewers (G. N. and R. O.) using the parameters previously used by Kumar et al. 15 In this scale, the following sections were in- 
| Statistical analysis
The association between the rs4998386 polymorphism and PD susceptibility was evaluated by calculating the pooled ORs and 95% CIs.
Heterogeneity between the included studies was determined with 
| RE SULTS

| Literature search
The results of the systematic literature search and selection are summarized in Figure 1 . We identified 58 articles through various database searching. After excluding duplicates, 26 articles remained.
Screening titles and abstracts of these 26 articles resulted in seven relevant abstracts. After inclusion and exclusion criteria, four studies were chosen for final data analysis.
| Study and patient characteristics
Our research included four studies with data from 12 different IIN) . 19 Allelic and genotypic data from each cohort are illustrated in Table 1 .
Of the 12 different cohorts included in our study, nine were from the United States, with all included participants of Caucasian race.
Methods of PD case and control ascertainment are given in Table 2 .
All included cohorts reached Hardy-Weinberg equilibrium in their control population. For genotyping, the TaqMan assay method was most commonly used among cohorts, though some applied the Illumina HumanOmni1-Quad v1.0, Sequenom MassARRAY and Perlegen platform. All cohorts used population-based controls with DNA sourced from whole blood, saliva, and buccal samples. According to qualityassessment tools, the methodological quality score ranged from 8 to 12, meaning no study analyzed was of low quality. Detailed study and patient characteristics are tabulated in Table 1 .
| Meta-analysis
Due to significant heterogeneity within studies in the allelic and dominant models, we used a random-effects model to estimate pooled
ORs and 95% CIs. The recessive model was without heterogeneity, so we used a fixed-effects model to estimate pooled ORs and 95% CIs. For all three genetic models, we sequentially excluded a single study from the pooled analysis and recalculated the summary ORs to check whether the summary ORs were significantly changed. The recalculated ORs also indicated stability of analysis. We performed a subgroup analysis based on the geographical location of the study (Europe vs America). In the allelic model, the rs4998386 polymorphism was not associated with PD in either Europeans (OR, 0.73; 95% CI, 0.49-1.09; P = .12) or white Americans (OR, 0.92; 95% CI, 0.77-1.11; P = .4). In the dominant model, the rs4998386 polymorphism was not associated with PD in either Europeans (OR, 0.87; 95% CI, 0.69-1.11; P = .26) or white Americans (OR, 1; 95% CI, 0.81-1.23; P = 1). Similarly, in the recessive model, the rs4998386 polymorphism was not associated with PD in either Europeans (OR, 1.12; 95% CI, 0.61-2.04; P = .72) or white Americans (OR, 1.13; 95% CI, 0.92-1.40; P = .24).
| D ISCUSS I ON
While the NMDAR is involved in synaptic plasticity and learning, its excessive activation results in excitotoxic neuronal damage, which is hypothesized to be a mechanism underlying several neurologic and neurodegenerative disorders. Increased glutamatergic transmission through the NMDAR is believed to play a role in the degeneration of the nigrostriatal dopaminergic pathway seen in PD pathophysiology. This deterioration leads to significant changes in striatal circuit structure and function, including modifications of the corticostriatal glutamatergic synaptic architecture and, consequently, loss of striatal synaptic plasticity and dopaminergic neurons. 20 In addition, continuous mass activation of NMDARs increases intracellular calcium loads and catabolic enzyme activities, triggering a cascade that leads to cell death. 8 Various animal models of PD have shown that NMDAR antagonists alleviate symptoms of PD. 13 In animal models, NMDAR
antagonists are effective antiparkinsonian agents and can reduce the complications of chronic dopaminergic therapy, such as "wearing off"
and dyskinesias. 21 Amantadine, an NMDAR antagonist, has been used clinically for treatment of dyskinesias and motor fluctuations in PD. 13 The neuronal NMDAR signaling has been found to be an important pathway in the development and progression of schizophrenia, Apart from GRIN2A, genetic alteration in other subunits of NMDARs are also associated with PD. A study by Wu et al found that polymorphisms in the GRIN1 and GRIN2B genes may serve as potential biomarkers for a reduced risk of PD among the Chinese population in Taiwan. 31 Lee et al and Abidin et al found that polymorphisms in the GRIN2B gene were associated with an increased risk of developing impulse-control behaviors among PD patients. 32, 33 Therefore, genetic alteration in subunits of NMDARs do have involvement in the pathophysiology of PD.
No study has primarily studied the association between the rs4998386 polymorphism of the GRIN2A gene of NMDAR and PD risk. Therefore,
we conducted a meta-analysis to examine the association between the rs4998386 polymorphism of the GRIN2A gene and PD risk.
Our meta-analysis found that the rs4998386 polymorphism is not associated with PD in Europeans or white Americans in any of the three genetic models, though our results may have been influenced by several factors. Given assumptions that PD is multi-determined and that the GRIN2A polymorphism alone is uncommon and small in effect, our power to detect genetic effects may have been reduced. PD is a multigenic disorder, with combined effects of multiple genotype polymorphisms predisposing carriers to increased PD risk. In two of the three genetic models, statistically significant heterogeneity was evident. Several aspects may contribute to this heterogeneity, including the diagnostic In addition, the following study limitations should be acknowledged. First, only people of European ancestry were included in our study. Therefore, results should be cautiously interpreted.
Second, some useful information, such as diagnostic criteria, clinical stage of PD, onset age of PD patients, and other environmental factors, was not available. Third, significant heterogeneity was evident in our meta-analysis. Lastly, gene-gene interaction and F I G U R E 5 Funnel plot for detection of publication bias in allelic model F I G U R E 6 Funnel plot for detection of publication bias in recessive model F I G U R E 7 Funnel plot for detection of publication bias in dominant model gene-environment interaction could not be analyzed due to lack of sufficient data.
| CON CLUS ION
Our meta-analysis found that the rs4998386 polymorphism of the 
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